Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Peripheral T-Cell Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Dexamethasone
Drug: Cisplatin
Drug: Romidepsin

First Posted Date: 2013-05-03

Last Posted Date: 2023-08-04

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 21

Registration Number: NCT01846390

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦
Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

and more 3 locations

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3

Completed

Conditions: Fallopian Tube Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms

Interventions: Drug: Trabectedin
Drug: DOXIL
Drug: Dexamethasone

First Posted Date: 2013-05-03

Last Posted Date: 2019-04-01

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 581

Registration Number: NCT01846611

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Phase 2

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: PEGPH20
Drug: Nab-paclitaxel
Drug: Dexamethasone
Drug: Gemcitabine
Drug: Enoxaparin

First Posted Date: 2013-04-25

Last Posted Date: 2020-07-20

Lead Sponsor: Halozyme Therapeutics

Target Recruit Count: 279

Registration Number: NCT01839487

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Lahey Clinic, Burlington, Massachusetts, United States

and more 48 locations

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Oprozomib
Drug: Dexamethasone

First Posted Date: 2013-04-16

Last Posted Date: 2020-07-13

Lead Sponsor: Amgen

Target Recruit Count: 65

Registration Number: NCT01832727

Locations: 🇫🇷
CHRU, Hopital Huriez - Department of Hematology, Lille CEDEX, France
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇫🇷
CHU Hotel Dieu - Service d'Hematologie Clinique, NANTES Cedex, France

and more 10 locations

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: carfilzomib
Drug: lenalidomide
Procedure: autologous hematopoietic stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2013-03-22

Last Posted Date: 2024-05-14

Lead Sponsor: University of Chicago

Target Recruit Count: 76

Registration Number: NCT01816971

Locations: 🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 2 locations

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Phase 2

Completed

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Carfilzomib
Drug: Rituximab
Drug: Dexamethasone

First Posted Date: 2013-03-18

Last Posted Date: 2022-04-13

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 7

Registration Number: NCT01813227

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Phase 2

Withdrawn

Conditions: Stage I Multiple Myeloma
Refractory Multiple Myeloma
Stage III Multiple Myeloma
Stage II Multiple Myeloma

Interventions: Drug: carfilzomib
Drug: dexamethasone
Other: laboratory biomarker analysis

First Posted Date: 2013-03-18

Last Posted Date: 2016-12-19

Lead Sponsor: Mayo Clinic

Registration Number: NCT01812720

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States